What top creators are saying about Injective(INJ)

Highlighted for reported protocol revenue, rising staking, real-world-asset activity, and trading and AI-agent use cases, but characterized as a higher-risk complement to ETH.

Holding up better than many tokens. An ETF approval was mentioned only as an unconfirmed rumor.

After observing a rally, the host advised against chasing and suggested waiting for weakness before considering a short or looking for a long near support.

A possible higher low and bullish divergence suggest conditional short-term upside, though reclaiming $8.15–$8.30 and Bitcoin's direction are important.

Described as breaking out with the potential to form a higher low; confirmation depends on the breakout holding.

The host described Injective as an older project with comparatively stronger market capitalization and trading volume than some weaker coins and noted it was below past levels. His interest focused on a liquidity pool rather than a long-term holding recommendation.

The host is watching a four-hour trend line for a potential breakout in about a day and a half; no trade direction or price levels were specified.

The AI compute index and expansion into options on traditional assets could increase usage and attention. The index offers up to 10x leverage, substantially magnifying risk.

The host identifies horizontal support near $6.60 but says the token could fall further to $6.

INJ was included in a Robinhood trading promotion. The discussion did not provide an investment outlook or price target.

Included in the ranked-token discussion without a specific score or detailed explanation; the host's general criteria emphasize users, revenue, and token value accrual.

Injective was holding an uptrend despite broader weakness, though $11.10 remains a significant resistance level.

A trader described a conditional long setup if the market first dipped sharply and swept lower levels; the entry was not confirmed.

The founder is bullish on the network’s potential to bring trading, tokenization, and financial tools together. Adoption, liquidity, and sustained trading activity remain key uncertainties, and no token valuation or specific investment recommendation is discussed.

The speaker is waiting for a possible pullback toward the low $7s to accumulate and sees a move to $13–$15 as possible if near-term resistance is cleared.

The host held some INJ and viewed its relative price resilience and circulating supply being close to fully diluted supply as positives; it was also among assets teased for Robinhood integrations.

The speaker described INJ as short-term bearish and was watching for a move toward the low-$7 range before considering additional trade setups.

The host sees the early-to-mid $7 range as support and a potential bounce area.

Injective was mentioned in a viewer request, but the speaker provided no analysis or trading view.

Listed among coins the speaker considered inexpensive or worth watching, without a specific price target or detailed investment case.

Named as one of the speaker’s preferred altcoins to accumulate; no specific price level or target was provided.

The speaker likes Injective as a higher-risk altcoin tied to tokenized real-world assets, citing favorable tokenomics, full circulation, and strong capitalization.

After previously appearing strong and then selling off, INJ was considered for a short around $8.21–$8.22.

The speaker said Injective appeared especially active compared with prior cycles and could reach at least half of its previous all-time high. The scenario is speculative and has no stated timeline.

The host says he held Injective partly as a bet on an RWA-focused layer-one network, while treating such positions as short-term trades.

Mentioned as a tokenization protocol that could potentially benefit from sector growth, without a specific endorsement or investment recommendation.

The host likes Injective's fully circulating token supply and developing uptrend, and considers it a possible real-world asset investment.

The speaker considers it somewhat expensive and prefers to wait for a lower entry.

The speaker says the chart looks bullish and regrets not buying more earlier, but acknowledges that the preferred $7 entry may not occur.

The hosts cited poor longer-term price performance, without identifying specific catalysts or targets.

The bullish thesis cites tokenization initiatives, an SEC-registered transfer agent, a trade-receivables partnership, 7 million tokens burned, and more than half of supply locked in staking.

The host highlighted a strong recent move but noted that it failed to hold a breakout level, which could be a warning sign.

Cited as having risen 27% during a recent dip in Bitcoin dominance; the move is an example, not an endorsement or lasting-momentum claim.

The speaker is positive on Injective's real-world-asset tokenization opportunity, fully circulating supply, and continued development.

The speakers discussed shorting after a strong rally on ETF news, but warned that a break above 9.60 could lead to further upside and favored waiting for a higher push.

The host notes that INJ rose 72% over the prior month and had performed well previously, but provides no detailed thesis or recommendation.

Possible ETF approval was only an unconfirmed rumor, and the host warned that resistance near $11–$12 could limit further gains.

Mentioned as a project of interest in tokenized stocks and real-world assets, and included in a conditional broad altcoin view without individual analysis.

The chart outlook was considered bullish above $6.41, although weakness in Bitcoin could undermine the setup.

Listed among the host’s preferred altcoins for the current cycle, but viewed as a potential buy on a pullback rather than an immediate buy.

The first order filled, and the token was described as looking strong; the speaker is monitoring it before deciding whether to add.

The speaker called Injective a major opportunity, is building positions around pullbacks, and reported an earlier filled order was up 21%.

Injective’s Trench Treasury reportedly acquired 10% of NinjaCat supply; the Solana-launched project lets users earn INJ from revenue.

The speaker is building a position in stages, with an order at $6.60 filled and additional orders at $6.10 and $5.80.

After falling about 11% over 24 hours, INJ was viewed as a potential accumulation opportunity. The speaker planned to deploy about 60% of intended capital across limit orders while retaining cash.

Injective was described as making a renewed push into real-world-asset tokenization, emphasizing retail-focused on-chain tokenized-stock trading. Its established ecosystem was highlighted, but no price target or specific recommendation was given.

The speaker considers INJ a preferred altcoin opportunity for the broader cycle and may build a position near the accumulation range, while allowing for further downside.

The speaker describes a downtrend breakout and favorable chart risk-reward, while advising staged entries and profit-taking rather than assuming the breakout will continue.

The speaker described an existing long plan with one-hour-candle confirmation and a possible lower entry near $7.48 if price pulled back.

Cited as trading roughly 55% above its 200-day simple moving average, highlighting potential correction risk. The speaker explicitly says the illustrative move from about $7.50 to $4.80 is not a prediction.